Francesco Patalano Selected Research

Glycopyrrolate (Glycopyrronium Bromide)

2/2022	Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial.
1/2019	Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME.
1/2018	Indacaterol/glycopyrronium: a dual bronchodilator for COPD.
1/2018	Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL Study.
1/2018	Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.
1/2018	Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.
1/2018	Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.
1/2018	Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.
1/2017	Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.
1/2017	Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Francesco Patalano Research Topics

Disease

30	Chronic Obstructive Pulmonary Disease (COPD) 02/2022 - 06/2014
4	Dyspnea (Shortness of Breath) 03/2016 - 01/2015
3	Asthma (Bronchial Asthma) 01/2020 - 01/2016
3	Pneumonia (Pneumonitis) 01/2017 - 01/2015
3	Obstructive Lung Diseases (Obstructive Lung Disease) 01/2017 - 06/2014
1	Cough 01/2020
1	Inflammation (Inflammations) 01/2018
1	Eosinophilia 11/2017

Drug/Important Bio-Agent (IBA)

20	Glycopyrrolate (Glycopyrronium Bromide)FDA LinkGeneric 02/2022 - 06/2014
19	indacaterolIBA 02/2022 - 06/2014
12	Muscarinic AntagonistsIBA 02/2022 - 06/2014
10	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2020 - 06/2014
9	Bronchodilator Agents (Bronchodilators)IBA 01/2018 - 06/2014
9	Fluticasone (Cutivate)FDA LinkGeneric 01/2018 - 01/2015
9	Salmeterol Xinafoate (Serevent)FDA Link 01/2018 - 01/2015
4	GoldIBA 01/2017 - 01/2015
3	Fluticasone-Salmeterol Drug Combination (Advair)FDA Link 01/2019 - 01/2016
3	Biomarkers (Surrogate Marker)IBA 01/2018 - 01/2016
3	indacaterol-glycopyrronium combinationIBA 11/2015 - 06/2014
2	vilanterolIBA 01/2016 - 06/2014
2	GSK573719IBA 01/2016 - 06/2014
1	GadoliniumIBA 02/2022
1	Pharmaceutical PreparationsIBA 01/2020
1	Mometasone Furoate (Nasonex)FDA LinkGeneric 01/2020
1	Tiotropium Bromide (Spiriva)FDA Link 01/2018
1	Indicators and Reagents (Reagents)IBA 01/2018
1	GlucocorticoidsIBA 01/2016
1	fluticasone furoate FDA Link 06/2014

Therapy/Procedure

6	Therapeutics 04/2020 - 06/2014
1	Drug Therapy (Chemotherapy) 01/2016